-+ 0.00%
-+ 0.00%
-+ 0.00%

Fosun Pharmaceutical announced that recently, its holding subsidiary Suzhou Futaba Pharmaceutical Co., Ltd.'s application for the registration of compound polyethylene glycol electrolyte dispersible drugs was approved by the State Drug Administration. The drug is approved for the treatment of chronic constipation in children aged 1 to 11 and fecal congestion in children aged 5 to 11. As of June 2026, the Group has invested a total of about 2.62 million yuan in research and development of this drug.

Zhitongcaijing·08/03/2026 08:25:04
Listen to the news
Fosun Pharmaceutical announced that recently, its holding subsidiary Suzhou Futaba Pharmaceutical Co., Ltd.'s application for the registration of compound polyethylene glycol electrolyte dispersible drugs was approved by the State Drug Administration. The drug is approved for the treatment of chronic constipation in children aged 1 to 11 and fecal congestion in children aged 5 to 11. As of June 2026, the Group has invested a total of about 2.62 million yuan in research and development of this drug.